LENZ Therapeutics, Inc. LENZ 深 滬
等待開盤 01-29 09:30:00 美东时间
18.65
-0.740
-3.82%
華盛通- 最 高19.80
- 今 開19.74
- 成交量 62.47万股
- 最 低 18.50
- 昨 收 19.39
- 總市值 5.25亿
- 52周最高 50.40
- 市盈率 靜 --
- 換手率 2.22%
- 52周最低 14.43
- 委 比 54.24%
- 總股本 2814.62万
- 歷史最高 230.79
- 量 比 0.44
- 振 幅 6.70%
- 歷史最低 3.92
- 每 手 1
- 風險率 7.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多LENZ Therapeutics Reports VIZZ Net Product Revenue Of ~ $1.6M In Q4 2025; Over 20,000 Prescriptions Filled Through Q4 2025; Rapid Uptake By Prescribing ECPs With Over 6,500 Unique Prescribing ECPs; More Than 55% Prescribed Multiple Times In Q4 2025
LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment
01-08 06:15
LENZ Therapeutics Acknowledges Adverse Event Reported To FDA; Says Patient Using VIZZ Experiences Retinal Tear, Cause Uncertain Due To Pre-Existing Risk Factors
LENZ Therapeutics, Inc. ("the Company") is aware of a recent adverse event report submitted to the U.S. Food and Drug Administration's ("FDA") Adverse Event Reporting System ("FAERS") database describing a retinal tear
2025-12-13 05:29
LENZ Therapeutics And Lotus Pharmaceutical Announces That Lotus Has Submitted A New Drug Application To South Korea's Ministry Of Food And Drug Safety For Vizz, Intended To Treat Presbyopia In Adults
LENZ Therapeutics, Inc. (NASDAQ:LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced that Lotus has submitted a New Drug Application (NDA) to the Ministry of Food and Drug Safety
2025-12-01 21:33
LENZ Therapeutics shares are trading lower. The company reported Q3 financial results.
LENZ Therapeutics shares are trading lower. The company reported Q3 financial r...
2025-11-05 22:26
LENZ Therapeutics Q3 EPS $(0.59) Beats $(0.67) Estimate, Sales $12.500M Beat $6.828M Estimate
LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.67) by 11.54 percent. This is a 55.26 percent decrease over losses of $(0.38) per share from
2025-11-05 21:06
LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025
LENZ Therapeutics will host a webcast on November 5, 2025, at 8:30 a.m. EST to discuss its third-quarter 2025 financial results and recent corporate updates. Participants can join via telephone using the provided numbers and code, or access the live webcast online at [www.LENZ-tx.com](https://www.globenewswire.com/Tracker?data=VKl91OEpK0WhJFPnCp6MwnPPNgip-sq5rjU408Sktjf4OnmEyXGIRo6cANW4mR4iqUQRzVBU2O2GNuezx-g15zzc_XyLQ1_FMIV0Ak706pk=). VIZZ™, the...
2025-10-29 12:00
美股大行评级 | 潜在涨幅344.44%！Rani Therapeutics获Maxim Group升目标价至10美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Rani Therapeutics Hldgs"买入"评级，目标价从5美元升至10美元；韦德布什：维持Corbus Pharmaceuticals"跑赢大市"评级，目标价从31美元升至38美元
2025-10-21 18:13
Raymond James Reiterates Outperform on LENZ Therapeutics, Raises Price Target to $50
Raymond James analyst Gary Nachman reiterates LENZ Therapeutics (NASDAQ:LENZ) with a Outperform and raises the price target from $40 to $50.
2025-10-21 01:18
美股大行评级 | 伯恩斯坦上调阿里巴巴目标价升至200美元；麦格理上调百度评级至"跑赢大市"，目标价升至176美元
今日重点评级关注：摩根大通：维持National Energy Services"超配"评级，目标价从10美元升至19美元；Piper Sandler：维持LENZ Therapeutics"超配"评级，目标价从51美元升至67美元
2025-10-13 11:26
Piper Sandler Maintains Overweight on LENZ Therapeutics, Raises Price Target to $67
Piper Sandler analyst Biren Amin maintains LENZ Therapeutics (NASDAQ:LENZ) with a Overweight and raises the price target from $51 to $67.
2025-10-10 20:52
